Last reviewed · How we verify
TAB014
At a glance
| Generic name | TAB014 |
|---|---|
| Also known as | TAB014 monoclonal antibody injection |
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration (PHASE3)
- TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAB014 CI brief — competitive landscape report
- TAB014 updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI